Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 13990.0
(-1.82%)
KRW 13990.0
(-1.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.74 Billion KRW | 65.88% |
| 2022 | -14.85 Billion KRW | -272.44% |
| 2021 | -14.19 Billion KRW | -909.66% |
| 2020 | -4.56 Billion KRW | -110.47% |
| 2019 | 6.23 Billion KRW | 88.59% |
| 2018 | 5.64 Billion KRW | 3.71% |
| 2017 | 4.65 Billion KRW | 155.56% |
| 2016 | -5.73 Billion KRW | -334.73% |
| 2015 | 2.44 Billion KRW | 84.74% |
| 2014 | 109.71 Million KRW | 120.79% |
| 2013 | -6.97 Billion KRW | -84.91% |
| 2012 | -5.45 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.36 Billion KRW | 118.02% |
| 2024 Q2 | -3.58 Billion KRW | -366.24% |
| 2023 Q3 | -1.66 Billion KRW | -7.06% |
| 2023 Q1 | -1.86 Billion KRW | 82.19% |
| 2023 FY | - KRW | 65.88% |
| 2023 Q4 | -3.28 Billion KRW | -96.65% |
| 2023 Q2 | -1.55 Billion KRW | 16.3% |
| 2022 FY | - KRW | -272.44% |
| 2022 Q4 | -10.45 Billion KRW | -53.48% |
| 2022 Q1 | -2.05 Billion KRW | 43.04% |
| 2022 Q2 | -5.21 Billion KRW | -153.94% |
| 2022 Q3 | -6.8 Billion KRW | -30.6% |
| 2021 Q1 | -1.18 Billion KRW | 60.54% |
| 2021 Q4 | -3.6 Billion KRW | -189.16% |
| 2021 FY | - KRW | -909.66% |
| 2021 Q2 | -552.33 Million KRW | 53.27% |
| 2021 Q3 | -1.24 Billion KRW | -125.72% |
| 2020 Q1 | 1.15 Billion KRW | -36.96% |
| 2020 Q3 | 52.62 Million KRW | -95.35% |
| 2020 Q4 | -2.99 Billion KRW | -5792.17% |
| 2020 FY | - KRW | -110.47% |
| 2020 Q2 | 1.13 Billion KRW | -2.43% |
| 2019 Q4 | 1.83 Billion KRW | 59.32% |
| 2019 Q3 | 1.15 Billion KRW | -33.82% |
| 2019 Q2 | 1.74 Billion KRW | 16.56% |
| 2019 Q1 | 1.49 Billion KRW | 197.19% |
| 2019 FY | - KRW | 88.59% |
| 2018 FY | - KRW | 3.71% |
| 2018 Q3 | 952.4 Million KRW | -13.17% |
| 2018 Q2 | 1.09 Billion KRW | 48.78% |
| 2018 Q1 | 737.22 Million KRW | -17.21% |
| 2018 Q4 | 503.43 Million KRW | -47.14% |
| 2017 Q3 | 1.36 Billion KRW | 43.17% |
| 2017 FY | - KRW | 155.56% |
| 2017 Q2 | 952.3 Million KRW | 2992.18% |
| 2017 Q1 | -32.92 Million KRW | 99.39% |
| 2017 Q4 | 890.49 Million KRW | -34.69% |
| 2016 Q3 | -1.13 Billion KRW | -1008.49% |
| 2016 Q4 | -5.36 Billion KRW | -371.7% |
| 2016 FY | - KRW | -334.73% |
| 2016 Q1 | 640.02 Million KRW | 2087.42% |
| 2016 Q2 | 125.19 Million KRW | -80.44% |
| 2015 Q3 | 1.11 Billion KRW | 91.47% |
| 2015 Q1 | 697.3 Million KRW | 158.49% |
| 2015 FY | - KRW | 84.74% |
| 2015 Q4 | 29.25 Million KRW | -97.38% |
| 2015 Q2 | 583.24 Million KRW | -16.36% |
| 2014 Q3 | 1.17 Billion KRW | 335.57% |
| 2014 Q1 | -388.42 Million KRW | 84.45% |
| 2014 FY | - KRW | 120.79% |
| 2014 Q4 | 269.76 Million KRW | -76.99% |
| 2014 Q2 | 269.16 Million KRW | 169.3% |
| 2013 Q2 | -1.76 Billion KRW | -132.48% |
| 2013 Q4 | -2.49 Billion KRW | -86.0% |
| 2013 Q3 | -1.34 Billion KRW | 23.82% |
| 2013 FY | - KRW | -84.91% |
| 2013 Q1 | -758.36 Million KRW | -158.62% |
| 2012 Q4 | 1.29 Billion KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 6.54 Billion KRW | 294.677% |
| ST Pharm Co.,Ltd. | 52.48 Billion KRW | 124.29% |
| ABL Bio Inc. | 2.1 Billion KRW | 705.787% |
| Cellid, Co., Ltd. | -7.68 Billion KRW | -65.927% |